Meeting
2017 ASCO Annual Meeting
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in advanced cancers.
Authors
Shiraj Sen
The University of Texas MD Anderson Cancer Center, Houston, TX
Shiraj Sen , Sarina Anne Piha-Paul , Shumei Kato , Daniel D. Karp , Filip Janku , Siqing Fu , Aung Naing , Shubham Pant , Apostolia Maria Tsimberidou , Vivek Subbiah , Razelle Kurzrock , Funda Meric-Bernstam , David S. Hong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Chemotherapy
Clinical Trial Registration Number
NCT01113476
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2526)
DOI
10.1200/JCO.2017.35.15_suppl.2526
Abstract #
2526
Poster Bd #
18
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase I dose escalation study of hPV19, a novel humanized monoclonal antibody against vascular endothelial growth factor (VEGF), in patients with advanced solid tumors refractory to standard therapy.
First Author: Dongmei Ji
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase I study of trifluridine/tipiracil in combination with gemcitabine (gem) and nab-paclitaxel (nab-P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC).
First Author: Anita Ahmed Turk
Poster
2013 ASCO Annual Meeting
Pazopanib (P) and bevacizumab (B) in patients with metastatic renal cell carcinoma (mRCC) or other advanced refractory tumors: Phase I combination study final analysis.
First Author: Sylvie Negrier
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk